Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support




Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support

New York City, Jan. 05, 2026 (GLOBE NEWSWIRE) —

January 5, 2026

Citrus Burn is a citrus-derived dietary supplement formulated to support metabolism, daily energy levels, and thermogenic activity through plant-based ingredients.

As interest in natural metabolism support supplements continues to increase, CitrusBurn has gained attention for its focus on citrus peel extracts, particularly compounds derived from Seville orange peel. These ingredients are often discussed online in relation to the so-called “orange peel trick” for metabolism support, a growing wellness trend centered on citrus-based metabolic efficiency.

Unlike stimulant-heavy fat burners, CitrusBurn is positioned as a metabolism support formula designed to complement balanced nutrition and healthy lifestyle habits. The formulation reflects a modern shift toward botanical-based supplements that emphasize metabolic balance, energy regulation, and long-term sustainability rather than aggressive short-term weight loss claims.

For those researching CitrusBurn ingredients, scientific background, or current offers, the official Citrus Burn website provides detailed resources to help support informed decision-making.

The Orange Peel Trick Explained: Separating Online Buzz From Scientific Context

What Is the Orange Peel Trick for Metabolism Support?

The term “orange peel trick” has become popular across wellness blogs, social media platforms, and supplement review websites. In most cases, it refers to the use of citrus peel–derived compounds, particularly from bitter or Seville oranges, to support metabolic activity, appetite awareness, and energy balance.

Unlike consuming whole oranges, citrus peels contain higher concentrations of specific bioactive compounds that are present only in small amounts in the fruit’s juice or pulp. These compounds have been studied for their potential interaction with metabolic receptors, enzymes involved in fat oxidation, and thermogenic signaling pathways.

It is important to clarify that the orange peel trick is not a medical protocol or a guaranteed weight-loss method. Instead, it is a consumer-friendly term describing increased interest in citrus peel–based nutritional support for metabolism.

Orange Peel Method for Weight Support: Why Citrus Peels Are Different

Citrus peels differ significantly from citrus flesh in their phytochemical composition. The outer rind contains flavonoids, alkaloids, and aromatic plant compounds that serve protective functions for the fruit. In nutritional research, these same compounds are being evaluated for their antioxidant properties and potential roles in metabolic regulation.

Seville orange peel, in particular, has been examined for compounds linked to thermogenic activity and energy expenditure. Rather than acting as harsh stimulants, these compounds are associated with metabolic signaling pathways related to fat utilization and energy efficiency.

CitrusBurn incorporates citrus peel extracts as part of a broader botanical blend designed to support metabolism without relying on excessive caffeine or synthetic stimulants. This is a key distinction often noted when comparing citrus-based metabolism supplements to traditional stimulant-driven fat burners. Find out more about the Orange Peel Trick here and how it works exactly!

Why the Orange Peel Approach Appeals to Modern Consumers

The growing popularity of citrus peel–based supplements can be attributed to several factors:

• Plant-based ingredients: Citrus peels align with clean-label and natural wellness preferences
• Lower stimulant perception: Often viewed as gentler than high-caffeine metabolism products
• Metabolic efficiency focus: Emphasizes balance and sustainability over forced calorie burn
• Easy daily use: Typically integrates into everyday routines without strict timing rules

As awareness around long-term metabolic health continues to grow, many consumers are turning toward metabolism support supplements that prioritize consistency, balance, and sustainable results rather than short-term intensity.

Introducing Citrus Burn: A Citrus-Based Metabolism Support Supplement

CitrusBurn is a citrus-based metabolism support supplement formulated to help support thermogenesis, energy utilization, and appetite awareness through a blend of citrus-derived botanicals and complementary plant-based nutrients.

As consumer interest in natural metabolic health continues to grow, Citrus Burn has positioned itself as a metabolism-focused dietary supplement rather than a rapid weight-loss product. According to publicly available product information, the formula is designed to work alongside balanced nutrition and lifestyle habits, supporting metabolic efficiency instead of promoting extreme or short-term results.

Rather than relying on a single active compound, CitrusBurn uses a multi-ingredient formulation strategy commonly found in modern nutraceuticals. This approach reflects the understanding that metabolic function involves multiple biological pathways, including energy production, fat utilization, and glucose regulation.

CitrusBurn is primarily marketed toward adults seeking ongoing metabolic support, particularly individuals who feel their metabolism has slowed with age despite maintaining consistent dietary and physical activity routines.

How CitrusBurn Uses Ingredient Synergy for Metabolic Support

Ingredient synergy is a formulation concept in which multiple complementary compounds are combined to support broader physiological processes more effectively than isolated ingredients. In metabolism support supplements, this often involves blending ingredients associated with thermogenic activity, energy metabolism, and blood sugar balance.

Citrus Burn emphasizes citrus peel extracts alongside botanicals commonly linked to metabolic health and energy regulation. While many of the individual ingredients included in CitrusBurn have research supporting their standalone use, the finished formulation itself is positioned as a general wellness supplement rather than a clinically validated treatment.

This positioning aligns with dietary supplement regulations, which require products to focus on supporting normal bodily functions and overall wellness rather than making disease-related or therapeutic claims.

CitrusBurn Ingredients: What Is Included in the Formula?

CitrusBurn is formulated using a blend of citrus-derived botanicals and plant-based metabolic cofactors selected to support thermogenesis, appetite awareness, and efficient energy metabolism.

Instead of relying on high doses of caffeine or synthetic stimulants, the formula focuses on ingredient synergy, allowing multiple metabolic pathways involved in fat utilization and energy production to function together in a more balanced manner.

Seville Orange Peel (p-Synephrine)

Seville orange peel, sourced from bitter orange, contains p-synephrine, a compound that has been studied for its role in supporting thermogenic activity and metabolic function. Unlike traditional stimulants, p-synephrine is often associated with promoting fat oxidation and energy expenditure without producing strong stimulant effects such as jitteriness or energy crashes.

Spanish Red Apple Vinegar

Spanish red apple vinegar is commonly included in metabolism support formulas for its potential role in supporting appetite awareness and digestive comfort. This ingredient is often associated with helping users feel fuller after meals while also contributing to more stable blood sugar responses, which can support consistent energy levels throughout the day.

Green Tea Extract

Green tea extract is a well-researched botanical that contains catechins known for their antioxidant properties and association with fat metabolism. In metabolic supplements, green tea extract is commonly included to support fat oxidation, contribute to natural energy production, and provide cellular antioxidant support.

Himalayan Mountain Ginger

Himalayan mountain ginger has a long history of traditional use in digestive and metabolic support. In modern formulations, it is often included for its potential role in supporting digestive efficiency, managing cravings, and promoting overall metabolic balance.

Berberine and Korean Red Ginseng

Berberine and Korean red ginseng are included in CitrusBurn for their association with metabolic and hormonal balance. Berberine is commonly studied for its potential role in supporting glucose metabolism and insulin sensitivity, while Korean red ginseng is often linked to improved vitality, energy support, and stress resilience.

Note: Research generally supports individual ingredients rather than the finished Citrus Burn formulation. Individual results may vary.

Potential Benefits Commonly Associated With CitrusBurn

Citrus Burn is promoted as a daily metabolism support supplement designed to work in harmony with the body’s natural fat-burning and energy-production processes.

While individual outcomes can vary, citrus-based metabolic supplements like CitrusBurn are commonly associated with several potential benefits.

CitrusBurn is designed to support natural thermogenic activity, helping the body convert stored calories into usable energy more efficiently. Certain ingredients in the formula may also support appetite awareness, which can help reduce unnecessary snacking and manage cravings throughout the day.

Unlike stimulant-heavy products, Citrus Burn aims to promote clean, sustained energy, supporting steady energy levels, reduced crashes, and improved daily focus. Additionally, metabolic cofactors such as berberine and vinegar extracts are often associated with supporting balanced blood sugar levels and more consistent energy output.

CitrusBurn is intended to complement healthy nutrition and regular physical activity, making it suitable for individuals pursuing lifestyle-based weight and metabolic goals rather than quick-fix solutions.

CitrusBurn Pricing: Package Options and Cost Breakdown

CitrusBurn pricing is structured around multi-bottle packages designed to support consistent, long-term metabolic use. This tiered pricing approach is common among metabolism support supplements and allows customers to choose a package based on their usage goals and budget.

CitrusBurn Available Packages and Prices

• 6-Bottle Package (180-Day Supply)
  • Approximate cost: $49 per bottle
  • Lowest price per unit
  • Frequently includes free shipping
  • Most commonly selected option for long-term metabolic support
• 3-Bottle Package (90-Day Supply)
  • Approximate cost: $69 per bottle
  • Mid-range pricing option
  • Popular choice for first-time CitrusBurn users
• 2-Bottle Package (60-Day Supply)
  • Approximate cost: $79 per bottle
  • Entry-level package
  • Suitable for short-term evaluation before committing to a larger supply

Pricing and promotional discounts may vary depending on availability, seasonal offers, and demand. Multi-bottle packages are generally recommended for individuals seeking ongoing metabolism support.

Where to Buy CitrusBurn Safely

CitrusBurn is primarily available for purchase through the official CitrusBurn website. Buying directly from the source helps ensure product authenticity, proper storage conditions, and access to customer guarantees.

Recommended Purchasing Guidelines

To avoid counterfeit or expired products, consumers are typically encouraged to:

• Buy CitrusBurn only from the official website
• Avoid third-party marketplaces or unauthorized sellers
• Review current promotions, refund terms, and shipping details before ordering

CitrusBurn Shipping and Money-Back Guarantee

Most official Citrus Burn orders include secure checkout, tracked shipping, and access to a money-back guarantee that may extend up to 180 days. Purchasing directly from the official source helps ensure eligibility for customer support, refund policies, and verified product quality.

Below is a more SEO-optimized version of your content.
I’ve strengthened keyword targeting, heading hierarchy, semantic depth, and search intent alignment while keeping the meaning, tone, and compliance intact.

Primary SEO focus keywords integrated naturally:

• Citrus-based metabolism supplements
• Citrus-derived nutrients
• Orange peel trick
• Thermogenesis support
• Metabolic efficiency
• Natural thermogenic supplements
• CitrusBurn metabolism support

Understanding the Rising Interest in Citrus-Based Metabolism Supplements

Citrus-based metabolism supplements have gained significant attention in recent years as consumers seek natural, plant-derived options to support metabolic health, energy balance, and thermogenic activity. This growing interest reflects both advances in ingredient research and shifting consumer preferences toward sustainable, stimulant-free metabolic support.

Why Citrus-Derived Nutrients Are Gaining Attention in Metabolic Health

Over the past decade, citrus-derived nutrients have become an increasingly studied focus within nutritional science and the dietary supplement industry. Citrus fruits, and especially their peels, contain naturally occurring bioactive compounds such as flavonoids, alkaloids, and polyphenols. These compounds are being examined for their roles in metabolic signaling, antioxidant defense, and cellular energy regulation.

Citrus peels, in particular, have attracted attention because they contain higher concentrations of certain compounds that are not present in the same amounts within the fruit pulp. Research has explored these compounds in relation to fat oxidation, glucose metabolism, and appetite-related signaling pathways. This expanding body of ingredient-level research has contributed to online discussions commonly referred to as the “orange peel trick” or “orange peel hack” for metabolism and weight management.

While these phrases are widely used in consumer-focused content, nutrition researchers and supplement formulators emphasize that citrus-derived compounds should be evaluated within a broader metabolic framework. No single ingredient is viewed as a standalone solution, and metabolic health is influenced by multiple interconnected biological processes.

Growing Consumer Demand for Natural Thermogenic Support

Global demand for metabolism support supplements has accelerated, particularly among adults over the age of 35 who experience natural metabolic changes related to hormonal shifts, reduced thermogenesis, and altered energy expenditure. As awareness grows, many consumers are actively seeking alternatives to traditional stimulant-heavy fat burners, which are often associated with jitteriness, sleep disruption, and inconsistent energy levels.

Citrus-based thermogenic supplements have emerged as a category positioned between functional nutrition and conventional fat-burning products. These formulas typically emphasize plant-based ingredients, moderate metabolic activation, and compatibility with daily routines. CitrusBurn aligns with this positioning by combining citrus peel extracts with other botanicals commonly associated with metabolic support and energy balance.

Industry analysts note that the appeal of citrus-based metabolism supplements is driven not only by ingredient research but also by consumer preferences for clean-label formulations, non-habit-forming products, and solutions that support gradual, sustainable metabolic outcomes rather than rapid or extreme weight fluctuations.

The Science Behind Thermogenesis and Metabolic Efficiency

What Is Thermogenesis and Why It Declines With Age

Thermogenesis refers to the body’s natural process of producing heat through calorie expenditure. This process plays a key role in regulating body temperature, supporting digestion, and determining how efficiently the body converts stored energy into usable fuel. A significant portion of daily calorie burn occurs through thermogenic activity rather than physical movement alone.

Scientific research suggests that thermogenic efficiency tends to decline with age, particularly after the mid-30s. Factors contributing to this decline may include reduced mitochondrial function, hormonal changes, shifts in insulin sensitivity, and alterations in nervous system signaling. As thermogenesis becomes less efficient, maintaining body composition can become more challenging even when diet and activity habits remain unchanged.

These age-related changes have prompted researchers to examine dietary compounds and botanical extracts that may help support thermogenic pathways without overstimulating the nervous system.

Thermogenic Resistance and Its Impact on Weight Management

Thermogenic resistance is a term increasingly used to describe reduced responsiveness to signals that initiate fat oxidation and calorie burning. In practical terms, this means the body may store energy more easily while becoming less efficient at accessing stored fat for fuel.

Although research in this area is ongoing, metabolic experts generally agree that supporting thermogenesis requires a multifactor approach that includes nutrition, physical activity, sleep quality, and hormonal balance. Supplements such as CitrusBurn are positioned as supportive tools within this broader lifestyle framework rather than as primary drivers of metabolic change.

By focusing on citrus-derived compounds associated with metabolic signaling, Citrus Burn is marketed as a formula intended to complement healthy habits rather than replace them.

Metabolism, Energy Production, and Fat Oxidation Explained

Metabolism refers to the complex network of biochemical processes responsible for converting food into energy, maintaining cellular structure, and supporting overall physiological balance. Fat oxidation is one component of metabolism and involves breaking down stored lipids into energy molecules that the body can use.

Certain plant-based compounds have been studied for their influence on enzymes and receptors involved in these processes. Citrus-derived flavonoids, alkaloids, and polyphenols have been examined for their potential roles in energy expenditure and metabolic signaling, particularly when used alongside other supportive nutrients.

CitrusBurn’s formulation reflects this ingredient synergy approach, emphasizing balanced metabolic support rather than isolated stimulation. This strategy aligns with evolving scientific perspectives that favor sustainable metabolic activation over aggressive, short-term calorie-burning methods.

Key Citrus-Derived Compounds and Their Roles in Metabolic Support

Citrus-derived compounds have become a major focus in the development of citrus-based metabolism supplements due to their association with thermogenesis, energy balance, and metabolic efficiency. These naturally occurring plant compounds are commonly studied for their ability to support calorie utilization without overstimulating the nervous system.

Citrus Peel Compounds and Thermogenic Signaling

Citrus peels contain naturally occurring alkaloids and flavonoids that have been studied for their interaction with adrenergic receptors involved in energy expenditure. These interactions may help support mild thermogenic activity, which can contribute to increased calorie burning when combined with regular physical activity and balanced nutrition.

Unlike high-dose synthetic stimulants, citrus-derived thermogenic compounds are often described as supporting metabolic alertness rather than triggering sharp spikes in nervous system stimulation. This more moderate effect profile has contributed to their widespread use in daily metabolism support supplements such as CitrusBurn.

Citrus Flavonoids and Antioxidant Support for Metabolic Health

Flavonoids found in citrus peels, including hesperidin and related polyphenols, are widely recognized for their antioxidant properties. Antioxidants play an important role in protecting cells from oxidative stress, a process closely associated with metabolic aging and reduced cellular efficiency.

By supporting antioxidant defenses, citrus-derived flavonoids may help maintain healthier metabolic function over time. This benefit is frequently discussed in the context of long-term metabolic wellness rather than short-term or rapid weight loss, aligning with the positioning of citrus-based metabolism supplements.

Energy Balance, Appetite Awareness, and Metabolic Regulation

Beyond thermogenic pathways, certain citrus-derived compounds have been examined for their potential influence on appetite signaling and blood sugar regulation. Stable energy levels and reduced fluctuations in hunger may help support healthier eating behaviors and more consistent dietary patterns.

CitrusBurn’s formulation approach emphasizes metabolic awareness rather than artificial appetite suppression. This positioning aligns with growing consumer demand for natural metabolism support solutions that work alongside lifestyle habits instead of overriding normal physiological signals.

Citrus Burn Ingredient Framework: A Research-Based Perspective

Ingredient-Level Research vs Finished Product Claims

Within the dietary supplement industry, scientific evidence is most commonly available at the individual ingredient level rather than for finished formulations. CitrusBurn follows this standard approach by incorporating botanicals and micronutrients that have been individually studied for roles related to metabolism, thermogenesis, energy regulation, and appetite awareness.

While CitrusBurn as a completed supplement has not been publicly linked to large-scale independent clinical trials, its formulation reflects ingredients that appear frequently in metabolic and thermogenic research literature. Understanding this distinction is essential for consumers evaluating metabolism support supplements responsibly.

Seville Orange Peel (Citrus aurantium) and Metabolic Support

Seville orange peel extract is one of the most widely discussed citrus-derived ingredients in metabolism-focused supplements. Research on Citrus aurantium has examined compounds such as p-synephrine, which may support metabolic rate through interactions with adrenergic receptor pathways involved in fat oxidation and energy expenditure.

Unlike ephedrine-based stimulants, p-synephrine is often described in scientific literature as having a milder cardiovascular impact when used responsibly and at appropriate doses. This characteristic has contributed to its inclusion in citrus-based thermogenic supplements designed for regular use.

Individual responses may vary depending on health status, stimulant sensitivity, and total caffeine intake from other sources.

Green Tea Extract and Fat Oxidation Support

Green tea extract is among the most extensively researched botanicals in metabolic health studies. Its catechins, particularly epigallocatechin gallate (EGCG), have been examined for their potential role in supporting fat oxidation and increasing energy expenditure.

Green tea extract is commonly included in metabolism supplements because it offers both antioxidant support and mild thermogenic activity. When combined with citrus-derived compounds, it may help support calorie utilization during physical activity and daily movement.

CitrusBurn includes green tea–derived compounds as part of a broader metabolic support framework rather than positioning them as a standalone fat-burning solution.

Botanical Cofactors and Cellular Energy Regulation

In addition to citrus peel and green tea extracts, CitrusBurn formulations typically include botanical cofactors associated with energy metabolism and nutrient utilization. These ingredients are selected to complement thermogenic compounds rather than amplify stimulant effects.

Such cofactors may help support mitochondrial function, carbohydrate metabolism, and cellular energy production. This formulation philosophy reflects modern supplement trends that prioritize metabolic efficiency, balance, and sustainability over aggressive stimulation.

How CitrusBurn Differs From Traditional Fat Burners

Citrus Burn is often compared to traditional fat burners due to its citrus-based formulation and non-stimulant-forward positioning. Understanding how CitrusBurn differs from conventional fat-burning supplements can help consumers evaluate whether citrus-based metabolism support aligns with their goals and tolerance preferences.

Stimulant-Heavy Fat Burners vs Citrus-Based Metabolism Support

Many traditional fat burners rely on high doses of caffeine, synthetic stimulants, or aggressive thermogenic compounds designed to rapidly increase heart rate and central nervous system activity. While some consumers seek this immediate surge of energy, others report side effects such as jitteriness, energy crashes, sleep disruption, or poor long-term tolerance.

CitrusBurn is positioned as a citrus-based metabolism support supplement that emphasizes smoother energy and daily usability rather than intense stimulation. This contrast is frequently highlighted in comparisons between citrus-derived metabolism supplements and conventional stimulant-heavy fat burners.

“Clean Energy” Support vs Jitter-Driven Stimulation

A commonly discussed concept in CitrusBurn reviews and consumer feedback is the idea of “clean energy.” This term is often used to describe energy support that feels steady and manageable, without the nervousness, anxiety, or abrupt energy drops associated with high-stimulant products.

Citrus-derived compounds and botanical extracts are frequently framed as supporting metabolic alertness and energy balance without overwhelming the nervous system. While individual responses vary, this positioning reflects broader wellness trends favoring sustainable energy over short-lived stimulation.

Appetite Awareness Compared to Appetite Suppression

Traditional fat burners often aim to suppress appetite through aggressive mechanisms, which may not support long-term dietary adherence. In contrast, citrus-based metabolism supplements are commonly marketed as supporting appetite awareness and natural satiety signals.

CitrusBurn’s formulation messaging aligns with this approach by emphasizing metabolic support alongside mindful eating habits, rather than presenting the supplement as a substitute for proper nutrition or a tool for extreme calorie restriction.

Safety, Tolerance, and Responsible Supplement Use

Who Typically Uses Citrus-Based Metabolism Supplements

CitrusBurn is generally marketed toward adults seeking metabolic support, particularly individuals who feel their metabolism has slowed with age. This includes people who maintain consistent diet and exercise routines but are looking for additional nutritional support to complement their lifestyle.

As with all dietary supplements, CitrusBurn is not intended to diagnose, treat, cure, or prevent disease. Individuals with medical conditions, stimulant sensitivities, or those taking prescription medications are encouraged to consult a healthcare professional before use.

Potential Interactions and Sensitivity Considerations

Some citrus-derived compounds may interact with medications, especially those processed through liver enzyme pathways. Individuals sensitive to stimulants should also consider their total daily intake of caffeine and related compounds from all dietary sources.

Responsible use includes following label directions, avoiding excessive stacking with other stimulant-containing supplements, and monitoring individual response over time.

Manufacturing Standards and Product Quality Considerations

CitrusBurn products are typically manufactured in facilities that comply with standard dietary supplement regulations, including Good Manufacturing Practices (GMP). These standards address ingredient sourcing, purity, and manufacturing consistency.

Although regulatory compliance does not equate to clinical effectiveness, it provides a baseline level of quality assurance for consumers navigating the metabolism supplement market.

Growing Consumer Demand for Citrus-Based Metabolism Supplements

Why Citrus-Derived Formulas Are Increasingly Popular

Over the past decade, consumer preferences in the supplement industry have shifted toward plant-based, clean-label, and naturally sourced products. Citrus-based metabolism supplements like CitrusBurn have emerged within this trend, benefiting from long-standing associations between citrus ingredients and wellness, digestion, and vitality.

Citrus flavors and botanical extracts are often perceived as fresher and more approachable than synthetic stimulant blends. This perception plays a meaningful role in consumer adoption, especially among individuals seeking metabolism support without aggressive stimulation.

Metabolism Support Demand After Age 35

Age-related metabolic slowdown is one of the most common reasons consumers explore metabolism supplements. Research and consumer surveys consistently show that adults over 35 often experience increased difficulty managing energy levels, appetite regulation, and body composition, even when diet and exercise habits remain consistent.

CitrusBurn and similar citrus-based metabolism supplements are frequently positioned toward this demographic, offering a formulation narrative focused on supporting natural metabolic pathways rather than promoting rapid or extreme weight loss.

This audience often prioritizes sustainable energy, digestive comfort, ingredient tolerance, and products that integrate easily into daily routines.

Clean-Label Preferences and Ingredient Transparency

Ingredient transparency has become a major decision factor for supplement buyers. Many consumers now review ingredient lists, sourcing information, and manufacturing practices before making a purchase.

CitrusBurn’s emphasis on recognizable botanical ingredients aligns with this clean-label trend. Citrus-derived compounds, green tea extracts, and botanical cofactors are generally more familiar to consumers than synthetic stimulants, contributing to higher perceived trust and confidence.

Conclusion: Should You Buy CitrusBurn?

Citrus Burn operates within the growing natural metabolism and weight-management supplement category, leveraging consumer interest in citrus-derived botanicals and functional nutrition.

While CitrusBurn is not a medical treatment or guaranteed solution, its formulation reflects current market preferences that favor plant-based ingredients, metabolic pathway support, and clean-label positioning.

As consumer awareness continues to evolve, citrus-based metabolism supplements like CitrusBurn are likely to remain central to discussions around metabolic health, lifestyle wellness, and nutraceutical innovation.

Final Note on Citrus Burn

Like all dietary supplements, CitrusBurn is best viewed as part of a broader wellness strategy that includes balanced nutrition, regular physical activity, and informed health decisions. For official product details, guarantees, and current availability, consumers are encouraged to visit the official CitrusBurn website.

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. CitrusBurn is a dietary supplement and is not designed to diagnose, treat, cure, or prevent any disease. Individual results may vary depending on health status, lifestyle, and personal factors. Always consult a qualified healthcare professional before starting any new supplement, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medications. Do not exceed recommended dosages. This content should not replace professional medical guidance, nutritional counseling, or personalized health advice from a licensed practitioner.

Project name: CitrusBurn

• Phone
  + 1 (800) 390-6035 (24/7)
• Email support@citrusburn.com.
• Advertise with us: Info@allprsolution.com

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock




Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Crinetics intends to use the net proceeds from the proposed offering, together with its cash, cash equivalents and investment securities, to fund its commercial activities in connection with the launch of PALSONIFY™, research and development of its product candidates, other research programs and other general corporate purposes, which may include, among other things, capital expenditures or working capital. Crinetics may also use a portion of the remaining net proceeds, together with its existing cash, cash equivalents and investment securities, to in-license, acquire, or invest in complementary businesses, technologies, products or assets; however, it has no current commitments or obligations to do so.

Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.

The securities described above are being offered by Crinetics pursuant to a shelf registration statement that became automatically effective upon its filing with the Securities and Exchange Commission (“SEC”). The proposed offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements relating to the offering, including the structure, timing, size and completion of the offering and the anticipated use of proceeds therefrom, and the grant of the option to purchase additional shares. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, the risks and uncertainties inherent in Crinetics’ business, including the risks and uncertainties described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended September 30, 2025, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

Investors: 
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075 

Plum Tree Launches 2026 with Expanded Access to Mental Health Care for Children and Adolescents




Plum Tree Launches 2026 with Expanded Access to Mental Health Care for Children and Adolescents

ST. CHARLES, Ill., Jan. 05, 2026 (GLOBE NEWSWIRE) — As families enter the new year, Plum Tree Psychology, a child and adolescent behavioral health practice serving Kane County and surrounding communities, is expanding access to care in response to the growing mental health needs of children, teens, and families.

January is historically one of the busiest times of year for pediatric mental health services, as academic pressure, anxiety, mood concerns, and learning challenges often surface or intensify following the holiday break. In anticipation of this annual surge, Plum Tree Psychology has increased appointment availability and service capacity to help families access timely support when it matters most.

“Families are telling us they want help sooner, not months down the road,” said David Savoia, Practice Manager at Plum Tree. “As we begin 2026, our focus is on reducing barriers to care and ensuring children and adolescents receive the support they need as early as possible.”

Expanding Access While Preserving Personalized Care

Plum Tree’s 2026 expansion includes a new office build-out, increased clinical availability and continued investment in comprehensive services for children and adolescents, including therapy, psychological and neuropsychological evaluations, and collaborative care with schools and pediatric providers.

While the practice continues to grow, leadership emphasizes that its core mission remains unchanged: providing individualized, multidisciplinary care in a supportive and welcoming environment.

“Growth only matters if it improves the experience for families,” Savoia added. “Our goal is to expand responsibly so children feel known, parents feel supported, and care never feels rushed or impersonal.”

Meeting a Rising Community Need

Local educators and healthcare providers report increasing emotional, behavioral, and learning-related concerns among students, particularly during the winter months. By expanding access at the start of the year, Plum Tree aims to help families address challenges before they escalate and to support children in both their emotional well-being and academic success.

Plum Tree also plans to continue strengthening partnerships with schools, pediatric practices, and community organizations throughout 2026 to promote early identification and coordinated care.

About Plum Tree

Plum Tree Psychology is a child and adolescent behavioral health practice dedicated to supporting the emotional, developmental, and psychological well-being of children, teens, and families. Serving Kane County and surrounding communities, Plum Tree provides evidence-based therapy, psychological and neuropsychological evaluations, and collaborative care designed to meet families where they are.

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0294f40f-1343-44a6-9cb3-205b7ad0ceb3

Contact information: hello@theplumtree.net / https://www.theplumtree.net/

Idorsia’s daridorexant in women during menopausal transition age with insomnia




Idorsia’s daridorexant in women during menopausal transition age with insomnia

• New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age
• Brigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms

Allschwil, Switzerland – January 5, 2026
Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insights from a randomized controlled trial” in Maturitas, a prestigious international journal of midlife health and beyond. This new analysis of the efficacy and safety of daridorexant in women aged 47–55 years with insomnia disorder – a population representative of the menopausal transition – is based on data from the Phase 3 randomized controlled trial (NCT03545191) published in Lancet Neurology and provides important insights into the management of insomnia during in midlife women.

One of the most prevalent and burdensome yet under-researched symptoms reported by women in the menopausal transition is sleep disturbance^1,2. Multiple factors, including hormonal changes, vasomotor symptoms (e.g. hot flushes, night sweats), psychological changes (e.g. mood symptoms, depression), development of other sleep disorders (e.g. restless legs syndrome, obstructive sleep apnea), and social demands (e.g. caregiving), may contribute, either triggering the onset of or exacerbating preexisting sleep disturbances³. Sleep disturbances can have a significant impact on physical and mental health, quality of life, and productivity⁴.

Key findings
Daridorexant 50 mg improved both sleep and daytime functioning compared to placebo.
Change from baseline at Month 3:

• Wake after sleep onset (WASO) was improved by ~43 minutes.
• Latency to persistent sleep (LPS) was improved by ~34 minutes.
• Self-reported total sleep time was improved by ~75 minutes.
• Daytime functioning and sleep quality scores were improved.

Furthermore, the incidence of somnolence and fatigue was low and comparable to placebo, and no increase in next-morning sleepiness was observed compared to placebo.

Dr Zoe Schaedel, BMedSci, BMBS, MRCGP, DRCOG, DFSRH, PGCertMedEd, General Practitioner, British Menopause Society (BMS) Menopause Specialist and co-author of the manuscript, commented: “Insomnia disorder affects approximately one in four women during the menopausal transition, yet is often underdiagnosed and certainly undertreated. This analysis shows that daridorexant 50 mg offered meaningful improvements in sleep and daytime functioning without compromising safety. It is essential that clinicians consider the diagnosis of insomnia disorder when sleep disturbances arise during the menopause transition rather than considering it merely secondary to menopausal symptoms, allowing access to evidence-based treatments.”

New Brigham and Women’s Hospital study
Principal investigators, Dr Bertisch and Dr Redline, from the Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, have selected daridorexant, Idorsia’s dual orexin receptor antagonist (DORA), to be included in a study, CELESTE, focused on menopause-related insomnia. The study will compare the effectiveness and safety of different approaches to treat menopause-related insomnia, including daridorexant as the only pharmacotherapy approved for the treatment of insomnia. Results will help clinicians and their patients when considering ways to treat menopause-related insomnia.

Delivering on the company’s commitment to advance the science of sleep and insomnia, Idorsia will be providing daridorexant at no cost, to support this ground-breaking study.

Antonio Olivieri, MD, Chief Medical Officer & Head of Global Medical Affairs at Idorsia commented: “We are excited for daridorexant to be included in this important study, as insomnia is associated with numerous serious health conditions, and is particularly common in women dealing with menopause. Daridorexant works differently from other insomnia medications by decreasing overactive wake signaling, which is a key cause of insomnia. We look forward to seeing the results and continuing to advance the science of insomnia.”

About the CELESTE study NCT07136415
Funded by the Patient-Centered Outcomes Research Institute (PCORI), the CELESTE study will include around 900 peri- and post-menopausal women with insomnia. Participants will receive treatment for 12 months and insomnia symptoms will be measured using surveys at the start of the study and again three, six and 12 months later. Treatments, including daridorexant, which is approved by the FDA for adults with insomnia, will be monitored to see if they work differently based on factors such the severity of hot flashes, presence of sleep apnea, and menopause stage. The study will be randomized with daridorexant being one of the three-arm study and is expected to be conducted over a 60-month period.

Global availability of daridorexant
Daridorexant is marketed as QUVIVIQ™ by Idorsia in the US, Canada, and multiple European countries, and is available in Japan, Hong Kong, and China through strategic partnerships.

The daridorexant Phase 3 registration program⁵
The global registration program demonstrated that 25mg and 50mg doses of daridorexant significantly improved sleep onset, sleep maintenance and self-reported total sleep time at months 1 and 3 compared to placebo. A major focus of the trials was to evaluate the impact of daridorexant on daytime functioning in patients with insomnia, as assessed by the IDSIQ. The sleepiness domain score of the IDSIQ was evaluated as a key secondary endpoint in both pivotal studies, and comparisons to placebo included control for multiplicity. Daridorexant 50 mg demonstrated a highly significant improvement in daytime functioning, as measured by the sleepiness domain at month 1 and month 3.

For the US:
Important Safety Information

Do not take QUVIVIQ if you fall asleep often at unexpected times (narcolepsy) or if you are allergic to QUVIVIQ or any of its ingredients.

QUVIVIQ may cause serious side effects, including:

• Decreased awareness and alertness. The morning after you take QUVIVIQ, your ability to drive safely and think clearly may be decreased. You may also have sleepiness during the day. Sleepiness may increase your risk of falls.
  • Do not take more QUVIVIQ than prescribed.
  • Do not take QUVIVIQ unless you are able to stay in bed for at least 7 hours before you must be active again.
  • Take QUVIVIQ at night within 30 minutes before going to bed.

QUVIVIQ is a federally controlled substance because it can be abused or lead to dependence.

Before taking QUVIVIQ, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of depression, mental illness, or suicidal thoughts or actions; drug or alcohol abuse or addiction; a sudden onset of muscle weakness (cataplexy); daytime sleepiness
• have lung or breathing problems, including sleep apnea
• have liver problems
• are pregnant or plan to become pregnant
• are breastfeeding or plan to breastfeed

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

• Taking QUVIVIQ with certain medicines can cause serious side effects. QUVIVIQ may affect the way other medicines work and other medicines may affect the way QUVIVIQ works.
• Do not take QUVIVIQ with other medicines that can make you sleepy unless instructed by your healthcare provider.

What should I avoid while taking QUVIVIQ?

• Do not drink alcohol while taking QUVIVIQ. It can increase the effects of alcohol, which can be dangerous.  
• Do not drive, operate heavy machinery, do anything dangerous, or do other activities that require clear thinking if you do not feel fully awake, or you have taken QUVIVIQ and have less than a full night of sleep (at least 7 hours), or if you have taken more QUVIVIQ than prescribed.

QUVIVIQ may cause other serious side effects, including:

• Worsening depression and suicidal thoughts. Call your healthcare provider right away if you have any worsening depression or thoughts of suicide or dying.
• Temporary inability to move or talk (sleep paralysis) for up to several minutes, or hallucinations while you are going to sleep or waking up.
• Temporary weakness in your legs that can happen during the day or at night
• Complex sleep behaviors such as sleepwalking, sleep-driving, preparing and eating food, making phone calls, having sex or doing other activities while not fully awake that you may not remember the next morning. Stop taking QUVIVIQ and call your healthcare provider right away if you experience a complex sleep behavior.

The most common side effects of QUVIVIQ are headache and sleepiness or tiredness.

These are not the only side effects of QUVIVIQ. Call your doctor for advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Notes to the editor

About insomnia
Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.

Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels.

The goals of managing insomnia are to improve sleep quality and quantity, as well as daytime functioning. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy.

About Dr Zoe Schaedel
Dr Zoe Schaedel, of Myla Health, is an experienced Menopause Specialist. She specialises in women’s health, menopause care, sexual health and contraception. She is an accredited specialist with the British Menopause Society (BMS) and is a member of the BMS Medical Advisory Council.

Dr Schaedel contributes to a number of national committees including the NHS England Menopause Improvement Programme and she has delivered talks and masterclasses nationally and to organisations on menopause and on the interplay between menopause, mental health and sleep. She has published articles on menopause in The Lancet and Post Reproductive Health. Dr Schaedel is a trainer for the British Menopause Society and loves to support clinicians who want to further their knowledge on women’s health. Dr Schaedel serves as a consultant to Idorsia.

References

1. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. Oct 2019;26(10):1213-1227. doi:10.1097/gme.0000000000001424
2. Schaedel Z, Holloway D, Bruce D, Rymer J. Management of sleep disorders in the menopausal transition. Post Reproductive Health. 2021;27(4):209-214. doi:10.1177/20533691211039151
3. Tobias L, Thapa S, Won CHJ. Impact of Sex on Sleep Disorders Across the Lifespan. Clinics in Chest Medicine. 2021/09/01/ 2021;42(3):427-442. doi:https://doi.org/10.1016/j.ccm.2021.04.005
4. Bolge SC, Joish VN, Balkrishnan R, Kannan H, Drake CL. Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings. Popul Health Manag. Feb 2010;13(1):15-20. doi:10.1089/pop.2009.0028
5. Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125-139. doi: 10.1016/S1474-4422(21)00436-1.

About Idorsia
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

• Press Release PDF

Zealand Pharma to present at the J.P. Morgan Healthcare Conference




Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Press release – No. 1 / 2026

Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44^th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California.

Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317741-zealand-pharma/webcast?gpu_only=true&kiosk=true.
A replay of the webcast will be available at https://www.zealandpharma.com/events/.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.  

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com

Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
RJamesOwens@zealandpharma.com

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783

DentPrime Publishes Comprehensive Patient Guidance Framework for Individuals Considering Dental Treatment Abroad




DentPrime Publishes Comprehensive Patient Guidance Framework for Individuals Considering Dental Treatment Abroad

Photo: DentPrime via FL Comms.

ANTALYA, Türkiye, Jan. 05, 2026 (GLOBE NEWSWIRE) — DentPrime today announced the publication of a comprehensive patient guidance framework designed to support individuals who are considering dental treatment abroad. The framework aims to provide structured, clinically grounded information to help patients better understand how to evaluate dental clinics, treatment plans and long-term care considerations before committing to overseas treatment.

The initiative responds to growing international interest in cross-border dental care, particularly among patients researching complex procedures such as dental implants in Turkey and restorative treatments that require careful planning and specialist involvement. DentPrime noted that while access to information has increased, patients are often required to make decisions based on fragmented or commercially focused content that does not fully explain clinical standards, risks or aftercare responsibilities.

“Dental treatment is not a commodity that can be assessed on price or appearance alone,” said a DentPrime spokesperson. “Patients need clear, medically sound information that explains not only what a treatment involves, but how it should be planned, delivered and supported over time. This framework was developed to help patients ask the right questions before making decisions.”

Focus on Clinical Experience and Specialist Care

A central element of the DentPrime framework highlights the importance of clinical experience and specialist qualifications. The guidance explains that while accessibility and communication are important, successful outcomes depend heavily on practitioner expertise, particularly in surgical and multi-stage treatments.

DentPrime advises patients to understand who will deliver their treatment, what their clinical background is and whether they have specific experience relevant to the proposed procedures. This is especially critical for implant-based care and extensive restorative treatments.

Consultation, Diagnostics and Informed Consent

The framework places strong emphasis on comprehensive consultation and diagnostic assessment as prerequisites for safe dental care. DentPrime notes that treatment plans developed without reviewing recent radiographs, three-dimensional dental imaging or a patient’s full medical history may lead to inaccurate diagnoses and unexpected complications.

According to the guidance, patients should expect a structured consultation process that includes advanced imaging, detailed oral examination and clear explanations of treatment options. Informed consent is identified as a critical step, requiring that patients fully understand potential risks, alternative approaches, healing timelines and financial considerations before treatment begins.

Material Quality and Laboratory Standards

Another key focus of the DentPrime guidance relates to material quality and laboratory standards used in restorative dentistry. The framework explains that long-term outcomes depend not only on clinical skill, but also on the quality and compatibility of materials used in implants, crowns and restorations.

Photo: DentPrime via FL Comms.

Discussions around zirconium crowns in Turkey, for example, often highlight the importance of material sourcing, digital design workflows and laboratory precision in achieving durable and natural-looking results. DentPrime encourages patients to seek transparency regarding the materials used and the standards applied during fabrication.

Pricing Logic and Treatment Planning

While cost differences between countries may influence patient decisions, DentPrime’s framework cautions against evaluating dental care solely on price. The guidance explains that extremely low fees may indicate compromises in diagnostics, materials, laboratory processes or follow-up care.

Photo: DentPrime via FL Comms.

Patients are encouraged to assess whether treatment proposals include realistic timelines, appropriate healing periods and comprehensive planning rather than focusing exclusively on headline pricing.

Aftercare and Long-Term Outcomes

The DentPrime framework places particular importance on aftercare and long-term treatment outcomes. Dental treatments, especially implant-based and restorative procedures, require ongoing maintenance, monitoring and patient compliance to ensure lasting success.

DentPrime advises patients to understand what follow-up care is provided, how complications are addressed and what guarantees apply to different components of their treatment. The guidance emphasises that long-term success depends on a combination of clinical execution, material quality and patient adherence to recommended care protocols.

Supporting Informed Decision-Making

DentPrime stated that the publication of the guidance framework reflects its broader commitment to patient education and evidence-based care. By consolidating clinical principles into a single, accessible resource, the organisation aims to support patients in making informed decisions that prioritise safety, transparency and long-term oral health.

“As interest in dental treatment abroad continues to grow, informed decision-making becomes increasingly important,” the DentPrime spokesperson added. “This framework is designed to help patients understand what high-quality dental care should look like, regardless of where it is delivered.”

About DentPrime

DentPrime is a dental clinic based in Antalya, Türkiye, providing dental healthcare services to international patients. The clinic aims to combine modern dental practices with structured treatment planning, comprehensive diagnostic processes, and a strong focus on patient information and communication.

DentPrime places particular emphasis on treatment pathways designed for patients travelling from abroad, prioritising detailed consultations, advanced imaging techniques, and personalised treatment plans. The clinic offers a range of services, including dental implant treatments, restorative dentistry procedures, and aesthetic dental care.

Contact:
Furkan Luleci
furkan@flcommunications.co.uk 

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/7ace0173-084e-4a38-aa21-fb1a124b01db

https://www.globenewswire.com/NewsRoom/AttachmentNg/ffc63df7-3fba-452c-ad30-61b7b0501c1f

https://www.globenewswire.com/NewsRoom/AttachmentNg/77eb72c3-25a3-4159-ab2c-d419274c78ac

A Better Life Therapy Joins the Lumina Therapy Alliance, Marking a Major Expansion of the Nation’s Gold Standard for Concierge, In-Person Mental Health Care




A Better Life Therapy Joins the Lumina Therapy Alliance, Marking a Major Expansion of the Nation’s Gold Standard for Concierge, In-Person Mental Health Care

Elizabeth Earnshaw’s nationally recognized Philadelphia practice brings elite clinical leadership, cultural influence, and high-touch care to Lumina’s growing employer-focused network

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Lumina Therapy Alliance, the nation’s premier collective of highly vetted, in-person mental health practices, today announced that A Better Life Therapy, the acclaimed Philadelphia-based practice founded and led by Elizabeth Earnshaw, LMFT, has officially joined its expanding national alliance.

This addition represents a defining moment for Lumina. A Better Life Therapy is widely regarded as a gold standard practice—known for its clinical sophistication, elevated client experience, and cultural impact well beyond its physical footprint. Led by Earnshaw, one of the most influential voices in modern therapy, the practice exemplifies the future of premium, relationship-based mental health care.

Elizabeth Earnshaw’s platform, @lizlistens, reaches a massive nationwide audience, shaping how millions understand relationships, attachment, trauma, and emotional health. Her work bridges deep clinical rigor with cultural relevance—bringing credibility, trust, and visibility that few practices in the country can match.

“A Better Life Therapy represents everything Lumina stands for,” said Dr. Daniel Selling, Founder of Lumina Therapy Alliance. “This is a practice that has earned national influence without compromising depth, integrity, or the in-person therapeutic experience. Elizabeth and her team have built something rare—beautiful brick-and-mortar spaces, extraordinary clinicians, and a level of care that truly changes lives. Their decision to join Lumina is a powerful signal of where high-end mental health care is headed.”

A Model Built for Today’s Employers

A Better Life Therapy’s entry into the Alliance significantly strengthens Lumina’s offering to employers seeking meaningful alternatives to underutilized teletherapy and EAP platforms. With a strong emphasis on high-touch concierge therapy, relational depth, and thoughtfully designed physical spaces, the practice delivers what today’s professionals increasingly demand: discretion, consistency, and real human connection.

For employers, this means access to a trusted, culturally respected practice that resonates with modern workforces—particularly leaders, creatives, and high-performing professionals navigating stress, relationships, trauma, and burnout.

“Joining Lumina felt like a natural alignment,” said Elizabeth Earnshaw, LMFT, Founder of A Better Life Therapy. “We believe deeply in the power of in-person work, intentional spaces, and care that meets people with nuance and humanity. Lumina is building something truly special—an alliance that honors clinical excellence while expanding access for individuals, families, and workplaces that want more than surface-level support.”

Raising the National Bar

Lumina Therapy Alliance was founded to curate the country’s most respected independent therapy practices into a single national standard—without sacrificing autonomy, culture, or quality. The Lumina Therapy Alliance now has over 250 clinicians! A Better Life Therapy joins a growing roster of elite practices that are redefining what premium mental health care looks like in the employer and concierge space.

This partnership reinforces Lumina’s mission: to offer employers and their teams real care, in real spaces, from real experts—and to move the industry beyond transactional, low-engagement mental health solutions.

About A Better Life Therapy

A Better Life Therapy is a Philadelphia-based psychotherapy practice known for its sophisticated, relationship-centered approach to mental health care. Founded by Elizabeth Earnshaw, LMFT, the practice specializes in attachment-based therapy, trauma-informed care, and relational healing for individuals, couples, and families. With beautifully designed in-person locations and a team of highly trained clinicians, A Better Life Therapy delivers an elevated, deeply human therapeutic experience rooted in clinical excellence and emotional depth. Elizabeth Earnshaw is also the creator of the nationally influential platform @lizlistens, which reaches millions and has helped reshape the public conversation around relationships and mental health.

About Lumina Therapy Alliance

Lumina Therapy Alliance is the nation’s leading collective of highly vetted, premium, in-person mental health practices built to serve modern employers and their workforces. Lumina partners with elite brick-and-mortar therapy groups across the country to deliver high-touch concierge mental health care—offering a powerful alternative to underutilized teletherapy and traditional EAP models. By uniting the best independent practices under a shared standard of excellence, Lumina is redefining how employers support mental health: with depth, discretion, and real clinical impact.

For more information contact us:

contact@luminatherapyalliance.com

Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer




Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer

— Proven financial and strategic leader with over two decades of experience driving organizational growth, operational excellence, and long‑term value creation —

WALTHAM, Mass. and SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Doug Pagán as its Chief Financial Officer.

“Doug brings a proven ability to guide organizations through pivotal inflection points, and his financial and strategic insight will be invaluable as we scale the organization and advance our clinical-stage pipeline, including the KAI-9531 global Phase 3 program,” said Ron Renaud, President and Chief Executive Officer of Kailera. “His leadership will play a key role in supporting growth, execution and long-term value creation, and we’re thrilled to welcome Doug to the Kailera team.”

“I’m excited to join Kailera at this transformative stage as the company progresses its clinical programs with the potential to reshape the future of obesity care,” said Doug Pagán, Chief Financial Officer of Kailera. “I look forward to partnering with the team to align financial strategy with execution as the organization scales and continues to make meaningful progress toward Kailera’s mission to deliver potentially category-leading treatments to people living with obesity.”

Doug brings more than two decades of experience in finance, investor relations, and capital formation across both public and private biopharmaceutical companies. Prior to joining Kailera, he served as Chief Financial Officer and Chief Operating Officer of Atalanta Therapeutics, where he currently serves on the Board of Directors. Before Atalanta, he served as Chief Financial Officer and Chief Operating Officer of Jnana Therapeutics. Prior to Jnana, Doug held Chief Financial Officer roles at Dicerna Pharmaceuticals, KSQ Therapeutics and Paratek Pharmaceuticals. He has previously held leadership roles at Acceleron and Biogen and has served on the Board of Directors of Ziopharm Oncology and Timberlyne Therapeutics. Doug earned his MBA in Finance & Accounting from Columbia Business School and a BSE in Chemical Engineering from Princeton University.

About Kailera Therapeutics
Kailera Therapeutics (Kailera) is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape. The lead product candidate, KAI-9531, is advancing to global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist with the potential to offer the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. Kailera is expanding the KAI-9531 franchise by developing a once-daily oral tablet formulation, KAI-9531-T, with the goal of providing a convenient oral option with the potential for highly differentiated tolerability and compelling weight loss. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist with the potential to improve upon the clinical profile of existing oral treatments, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Contact Information
Maura Gavaghan
Vice President, Corporate Communications and Investor Relations
maura.gavaghan@kailera.com

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill




LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy^® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD’s portfolio of branded obesity treatments.

This announcement broadens LifeMD’s long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare^® and Wegovy^® websites as a trusted telehealth provider, reflecting growing demand for convenient, clinically supported access to branded GLP-1 therapies.

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Wegovy^® pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events.¹ FDA approval of the Wegovy^® pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo.² The availability of an oral formulation is expected to broaden access to GLP‑1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue weekly injections.

“In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy^® pill to patients through LifeMD at the attractive cash-pay price, reinforcing our role as a preferred virtual destination for evidence-based medical weight management,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “We believe oral GLP-1 therapies represent an important next phase in obesity care. By supporting patients seeking care through Novo’s ‘Find a Doctor’ feature – alongside our own strong patient acquisition capabilities – we see a substantial long-term opportunity to further expand access and deliver a seamless experience that combines comprehensive clinical support with branded GLP-1 therapies shipped directly to patients’ homes.”

LifeMD’s integration with NovoCare^® Pharmacy provides streamlined access to Novo Nordisk’s FDA-approved GLP-1 medications, including Wegovy^® (injectable and oral) and Ozempic^®, at competitive cash-pay pricing. Patients receive a comprehensive, end-to-end experience that includes virtual visits with LifeMD’s affiliated medical group across all 50 states, ongoing clinical oversight, access to nationwide diagnostic testing, coordinated pharmacy fulfillment with fast shipping and real-time tracking, and simplified billing and payment.

“Innovation can only make a difference when people can access it. Our collaboration with LifeMD gives patients a trusted telehealth option where they can connect with a healthcare provider and begin authentic, FDA-approved treatment,” said Dave Moore, Executive Vice President, U.S. Operations, Novo Nordisk. “It’s another way we’re meeting people where they receive care and with the first and only FDA-approved oral GLP-1, Wegovy^® pill offers patients convenience and choice.”

All doses of the Wegovy^® pill are available by prescription to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications. Wegovy^® 1.5mg and 4mg pills are available to patients at $149 per month. After April 15, 2026, Wegovy^® 4mg pills will be available at $199 per month, and the 9mg and 25mg pills will be available at $299 per month.

¹ Wegovy prescribing information: https://www.novo-pi.com/wegovy.pdf 
² Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.

About LifeMD, Inc.

LifeMD^® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com  

Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com

Kriya Appoints Sachiyo Minegishi as Chief Financial Officer




Kriya Appoints Sachiyo Minegishi as Chief Financial Officer

Seasoned biotech executive with a track record of guiding corporate development, financial strategy and commercialization for public and private biopharma companies

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing life-changing gene therapies for conditions affecting millions of people around the world, today announced the appointment of Sachiyo Minegishi as Chief Financial Officer. Ms. Minegishi will oversee execution of Kriya’s corporate strategy, scaling of financial operations and planning for commercialization as the company advances multiple gene therapies through the clinic.

“Sachiyo brings sophisticated financial leadership as well as deep corporate development and commercialization experience in science-driven organizations. She has a strong understanding of how to scale biotech companies while maintaining a durable financial foundation,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya. “We are pleased to welcome Sachiyo to the Kriya executive team and look forward to her leadership during this next chapter of transformational growth at the company.”

Ms. Minegishi added, “Kriya’s mission to make gene therapies accessible could redefine the modality and deliver value to millions of patients and their families. I am excited to join Kriya at this pivotal stage as they progress multiple programs through the clinic and look forward to helping the team deliver on its mission.”

With more than two decades of biopharma experience, Ms. Minegishi has a proven track record of executive leadership—guiding financial strategy, capital markets execution, corporate development and commercial strategy to advance and launch therapeutics across public and private companies. She most recently served as the Chief Operating Officer at Rectify Pharma where she led execution across key areas of corporate strategy, finance and operations.

Prior to Rectify, Ms. Minegishi was the Chief Financial Officer at Akouos (acquired by Eli Lilly), and before this led cross-functional global development of a portfolio of gene therapies for Sickle Cell Disease at bluebird bio. Earlier in her career, Ms. Minegishi held leadership roles at Aegerion, Human Genome Sciences, Genzyme and Amgen, after beginning her career in investment banking at Merrill Lynch. Ms. Minegishi earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.

About Kriya Therapeutics
Our mission is to revolutionize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease. Kriya is a clinical-stage biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world. Our pipeline includes potentially transformational medicines in multiple therapeutic areas—including in ophthalmology, metabolic disease and neurology—built on our fully-integrated proprietary manufacturing and engineering platform. For more information, please visit www.kriyatx.com and follow us on LinkedIn and Twitter.

CONTACT: Media Contact:
Kelli Perkins
kelli@redhousecomms.com